Cost-benefit analysis of partnership working between fire and rescue and health services across England and Wales during the COVID-19 pandemic.

Publication date: Jul 12, 2023

Fire and rescue services undertook a range of additional activities to support the National Health Service (NHS) in managing extreme service demand during the COVID-19 pandemic. This study aims to examine the cost-benefit of partnership work between fire and rescue services and the NHS during the COVID-19 pandemic. England and Wales. A cost-benefit approach was used. Data relating to resources and outcomes was accessed from a National Data Portal commissioned by the National Fire Chiefs Council to record fire and rescue service responses throughout the pandemic. Literature-based economic estimates were applied to establish the potential cost-benefit of fire and rescue services undertaking support activities. Fire and rescue services commonly undertook eight activities to support ambulance services and hospitals in three key areas: (1) driving ambulances, (2) provision of personal protective equipment for healthcare workers and (3) mass testing and mass vaccination. Benefits outweighed costs for all activities. Total costs were estimated at lb93. 26 million and total benefits were between lb171. 46 million and lb1. 10 billion. This is the first economic evaluation of partnership working between fire and rescue and health services during a pandemic. Findings highlight the social and economic value of co-operation between fire and rescue services and the NHS and provides important evidence for informing public sector decisions regarding the allocation of resources in future public health crises.

Open Access PDF

Concepts Keywords
10billion COVID-19
Ambulances Health economics
Economic Health policy


Type Source Name
disease MESH COVID-19 pandemic
disease VO vaccination
disease MESH Emergency
disease IDO history
disease VO efficiency
disease VO effectiveness
drug DRUGBANK L-Valine
drug DRUGBANK Coenzyme M
disease VO effective
disease IDO intervention
drug DRUGBANK Etoperidone
disease VO time
disease MESH infection
disease VO vaccine
disease VO vaccine dose
disease MESH uncertainty
disease VO population
drug DRUGBANK Trestolone
disease IDO process
disease VO document
drug DRUGBANK Thiamine
disease VO report

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *